TH Theratechnologies Inc.

Lyne Fortin to Leave Theratechnologies by Year-End

Lyne Fortin to Leave Theratechnologies by Year-End

MONTREAL, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it was informed by Lyne Fortin, Senior Vice President and Chief Commercial Officer, that she will retire from the Company by year-end. Until then, she will remain in her position and will help in the transition of her files to her successor.

“I want to take this opportunity to thank Lyne for the significant contribution she made in making our Company become what it is today. Lyne brought the knowledge and experience that were needed to successfully make the transition towards becoming a commercial company and to help us launch Egrifta and Trogarzo™ in the United States,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

“I am proud of what we accomplished as a team during my five-year tenure as Chief Commercial Officer. I want to thank everyone at Theratechnologies for giving me the privilege and pleasure to be a part of a Company that successfully reinvented itself. It is now time for me to pass on the torch to bring Theratechnologies to yet another milestone on the path of growth and profitability,” said Lyne Fortin, Senior Vice President and Chief Commercial Officer.

About Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at  and on SEDAR at .

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information.

We refer potential investors to the “Risk Factors” section of our Annual Information Form dated February 6, 2018 available on SEDAR at for additional risks and uncertainties about Theratechnologies and its business. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Media inquiries:

Denis Boucher

Vice President, Communications and Corporate Affairs

Tel.: (514) 336-7800 

EN
28/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies Announces Completion of Acquisition by Future Pak

Theratechnologies Announces Completion of Acquisition by Future Pak MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the...

 PRESS RELEASE

Theratechnologies annonce la réalisation de l’acquisition par Future P...

Theratechnologies annonce la réalisation de l’acquisition par Future Pak MONTRÉAL, 25 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui la réalisation du plan d’arrangement pris en vertu du chapitre XVI – section II de la Loi sur les sociétés par actions (Québec) annoncé précédemment et auquel est partie CB Biotechnology, LLC (l’« Acquéreur »), un membre du même groupe que Future Pak, LLC (« Future Pak »), aux termes duquel l’Acqué...

 PRESS RELEASE

Theratechnologies reçoit l’approbation définitive du tribunal relative...

Theratechnologies reçoit l’approbation définitive du tribunal relativement au plan d’arrangement proposé visant son acquisition par Future Pak MONTRÉAL, 16 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui que la Société a obtenu l’ordonnance définitive de la Cour supérieure du Québec (chambre commerciale) approuvant le plan d’arrangement (l’« Arrangement ») pris en vertu du chapitre XVI – section II de la Loi sur les sociétés par ...

 PRESS RELEASE

Theratechnologies Receives Final Court Approval of Proposed Plan of Ar...

Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Pu...

 PRESS RELEASE

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to...

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”). At the special meetin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch